Panacos' first in class HIV drug
Panacos Pharmaceuticals has recently completed a Phase I clinical trial of the first-in-class HIV Maturation Inhibitor, PA-457, disrupts HIV maturation, a new target for antiretroviral drug discovery that was recently identified by Panacos scientists.
Panacos Pharmaceuticals has recently completed a Phase I clinical trial of the first-in-class HIV Maturation Inhibitor, PA-457, disrupts HIV maturation, a new target for antiretroviral drug discovery that was recently identified by Panacos scientists.
As a result of its novel mechanism of action, PA-457 retains activity against virus isolates resistant to the currently approved classes of HIV therapeutics including reverse transcriptase inhibitors and protease inhibitors. The increasing prevalence of these drug resistant HIV strains is a major problem for the treatment of HIV infection, driving the demand for the development of novel drugs like PA-457.
Orally bioavailable small molecule fusion inhibitors would offer considerable potential for the treatment of HIV infection, including viral strains resistant to currently approved drugs. Based on its proprietary high-throughput assay system for identification of small molecule fusion inhibitors, Panacos believes it has a leading position in the discovery of such compounds.